Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel

Melanie D. Swift, Laura E. Breeher, Aaron J. Tande, Christopher P. Tommaso, Caitlin M. Hainy, Haitao Chu, M. Hassan Murad, Elie F. Berbari, Abinash Virk

Research output: Contribution to journalArticlepeer-review

Abstract

In a large cohort of United States healthcare personnel without prior coronavirus disease 2019 (COVID-19) infection, 94 382 doses of messenger RNA (mRNA) COVID-19 vaccine were administered to 49 220 individuals. The adjusted vaccine effectiveness following 2 doses of each of the 2 available brands of mRNA vaccine exceeded 96%.

Original languageEnglish (US)
Pages (from-to)e1376-e1379
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume73
Issue number6
DOIs
StatePublished - Sep 15 2021

Keywords

  • COVID-19
  • healthcare personnel
  • mRNA
  • SARS-CoV-2
  • vaccine effectiveness

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel'. Together they form a unique fingerprint.

Cite this